ENDRA Life Sciences Inc.
NDRA
$5.50
-$0.42-7.10%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 33.25% | 10.77% | 19.63% | 38.24% | -22.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.76% | -10.65% | -8.26% | 2.82% | -35.54% |
| Operating Income | -5.76% | 10.65% | 8.26% | -2.82% | 35.54% |
| Income Before Tax | 9.20% | 8.36% | 1.26% | -14.39% | 25.83% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 9.20% | 8.36% | 1.26% | -14.39% | 25.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 9.20% | 8.36% | 1.26% | -14.39% | 25.83% |
| EBIT | -5.76% | 10.65% | 8.26% | -2.82% | 35.54% |
| EBITDA | -5.96% | 10.40% | 7.77% | -3.59% | 35.30% |
| EPS Basic | 91.25% | 85.46% | -- | -- | -- |
| Normalized Basic EPS | 91.25% | 85.46% | -- | -- | -- |
| EPS Diluted | 91.25% | 85.46% | -- | -- | -- |
| Normalized Diluted EPS | 91.25% | 85.46% | -- | -- | -- |
| Average Basic Shares Outstanding | 881.52% | 13,112.18% | -- | -- | -- |
| Average Diluted Shares Outstanding | 881.52% | 13,112.18% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |